▲ +174.39% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Gamida Cell in the last 3 months. The average price target is $20.25, with a high forecast of $27.00 and a low forecast of $14.00. The average price target represents a 174.39% upside from the last price of $7.38.
The current consensus among 5 contributing investment analysts is to buy stock in Gamida Cell. This Buy consensus rating has held steady for over two years.
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.